Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:51:37.712Z.
Calculation as of: 2026-10-06T18:51:37.712Z.
Quote observation: 2026-10-06T18:50:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26a6c2e450689c32f4e4e5954cf906f309ed45562a8b136dc87c806878a45fac
PEG RATIO
N/A
Market Cap
$5.95B
PEG Ratio
N/A
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.06
Market Cap
$5.87B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $5.93B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | N/A | 0.03 | 0.06 | 0.06 |
| Kodiak Sciences Inc. (KOD)vs › | $5.90B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.90B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | N/A | N/A | N/A | N/A |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.22B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.64B | N/A | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | N/A | 1.53 | 1.61 | 1.46 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.47B | N/A | N/A | N/A | N/A |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.50B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
